FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
Daniel Cejka(Krankenhaus der Elisabethinen), Volker Wacheck(Taiho Oncology (United States))
Cited by 39
Related Papers
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
|Cancer Chemotherapy and Pharmacology|2017|31